

---

## Product Data Sheet

---

Product Name: CPTH2 (hydrochloride)

Cat. No.: GC14428

**Chemical Properties**

Cas. No. 2108899-91-6

Chemical Name 2-[4-(4-chlorophenyl)-2-thiazolyl]hydrazone-cyclopentanone, monohydrochloride

SMILES C1C(C=C1)=CC=C1C2=CSC(N/N=C3CCCC\3)=N2.ClFormula  $C_{14}H_{14}ClN_3S \cdot HCl$ 

M.Wt 328.3

Solubility  $\leq 5\text{mg/ml}$  in ethanol;  $16\text{mg/ml}$  in DMSO;  $5\text{mg/ml}$  in dimethyl formamideStorage Store at  $-20^\circ\text{C}$ General tips For obtaining a higher solubility, please warm the tube at  $37^\circ\text{C}$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^\circ\text{C}$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure **Background**

CPTH2 is an inhibitor of HAT activity of Gcn5.

Histone acetyltransferases (HATs) has been identified to add the acetyl group on the specific lysine of histone H3 and H4 N-termini, and such signatures are able to increase the accessibility of the underlying chromatin at specific genes or over vast regions of the genome. Gcn5p is a chimeric protein made up of a number of functional domains.

In vitro: Previous study identified a novel molecule named CPTH2, which was selected based on its inhibitory effect on the growth of a gcn5Delta strain. This study indicated a specific chemical-genetic interaction between CPTH2 and HAT Gcn5p, suggesting that CPTH2 could inhibit the dependent functional network of Gcn5p. In addition, CPTH2 was found to be able to inhibit an in-vitro HAT reaction, which could be reverted by increasing concentration of histone H3 [1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

In vivo: In vivo, CPTH2 could decrease the acetylation of bulk histone H3 at the specific H3-AcK14 site [1].

Clinical trial: Up to now, CPTH2 is still in the preclinical development stage.

Reference:

[1] F. Chimenti, B. Bizzarri, E. Maccioni, et al. A novel histone acetyltransferase inhibitor modulating Gcn5 network: Cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl]hydrazone. *Journal of Medicinal Chemistry* 52, 530-536 (2009).

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**